Having trouble viewing this email? View in your browser.
Weekly News
12 October 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

Call to join the ESCMID Scientific Affairs Subcommittee is closing soon!

Only one week is left to apply to join the Scientific Affairs Subcommittee within the theme of Epidemiology, Public Health and Vaccinology. Apply now to join and take a leadership role in the scientific activities of ESCMID.

ESCMID members interested in applying can find the full call document here.

The deadline to apply is 20 Oct 2021

World Health Summit – 24-26 October 2021

Don’t miss the World Health Summit, which is free to join online! This event will take place from 24 – 26 October 2021. Find out more about the summit and the great programme on the event website. ESCMID is proud to be an academic partner of the World Health Summit.

HMA/EMA Big Data Stakeholder Events

EMA invites you to two virtual events. On 30 November 2021, a webinar on Learning Initiative for Optimal Use of Big Data, and 7 December 2021, the 2nd EU Big Data Stakeholder. To enable wide participation, the events will be broadcast and a recording made public. Registration will open soon.

Public Consultation Phase open for new ESCMID Guidelines

“ESCMID rapid guidelines for assessment and management of long COVID” is undergoing public consultation. Check here to participate. The deadline to provide feedback and comments is 9 November 2021.

Call to join the ESCMID Guidelines Subcommittee

ESCMID is selecting new members of the Guidelines Subcommittee. ESCMID members interested in joining the subcommittee can find the full call document here. The deadline to apply is 1 November 2021.

Call to select a methodologist in medical guidelines development

ESCMID is currently seeking applications for an experienced methodologist for medical guidelines development. This position will be supporting the drafting groups of ESCMID guidelines in various aspects. Interested persons can learn more and apply by 15 November on the ESCMID website.

Real-world safety data for SARS-CoV-2 vaccine

The BNT162b2 vaccine showed a reassuring safety profile in clinical trials, but some neurological complaints in proximity to vaccination have received special public attention. The data suggests that there is no association between vaccination, Bell’s palsy, herpes-zoster or GBS.